369 related articles for article (PubMed ID: 10642802)
1. High-dose busulfan/melphalan as conditioning for autologous PBPC transplantation in pediatric patients with solid tumors.
Diaz MA; Vicent MG; Madero L
Bone Marrow Transplant; 1999 Dec; 24(11):1157-9. PubMed ID: 10642802
[TBL] [Abstract][Full Text] [Related]
2. High-dose busulfan and melphalan as conditioning regimen for autologous peripheral blood progenitor cell transplantation in high-risk neuroblastoma patients.
Molina B; Alonso L; Gonzalez-Vicent M; Andion M; Hernandez C; Lassaletta A; Cormenzana M; Lopez-Ibor B; Villa M; Molina J; Diaz MA
Pediatr Hematol Oncol; 2011 Mar; 28(2):115-23. PubMed ID: 21299340
[TBL] [Abstract][Full Text] [Related]
3. High-dose busulphan/melphalan with autologous stem cell rescue in Ewing's sarcoma.
Atra A; Whelan JS; Calvagna V; Shankar AG; Ashley S; Shepherd V; Souhami RL; Pinkerton CR
Bone Marrow Transplant; 1997 Nov; 20(10):843-6. PubMed ID: 9404924
[TBL] [Abstract][Full Text] [Related]
4. Megachemotherapy followed by autologous stem cell transplantation in children with Ewing's sarcoma.
Drabko K; Zawitkowska-Klaczynska J; Wojcik B; Choma M; Zaucha-Prazmo A; Kowalczyk J; Gorczynska E; Toporski J; Kałwak K; Turkiewicz D; Chybicka A
Pediatr Transplant; 2005 Oct; 9(5):618-21. PubMed ID: 16176419
[TBL] [Abstract][Full Text] [Related]
5. High-dose sequential chemotherapy and autologous stem cell reinfusion in advanced pediatric solid tumors.
Chan KW; Petropoulos D; Choroszy M; Herzog C; Jaffe N; Ater J; Korbling M
Bone Marrow Transplant; 1997 Dec; 20(12):1039-43. PubMed ID: 9466276
[TBL] [Abstract][Full Text] [Related]
6. High-dose busulfan and melphalan as conditioning regimen for autologous peripheral blood progenitor cell transplantation in high-risk ewing sarcoma patients: a long-term follow-up single-center study.
Diaz MA; Lassaletta A; Perez A; Sevilla J; Madero L; Gonzalez-Vicent M
Pediatr Hematol Oncol; 2010 May; 27(4):272-82. PubMed ID: 20426518
[TBL] [Abstract][Full Text] [Related]
7. Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Société Française des Cancers de l'Enfant.
Oberlin O; Rey A; Desfachelles AS; Philip T; Plantaz D; Schmitt C; Plouvier E; Lejars O; Rubie H; Terrier P; Michon J;
J Clin Oncol; 2006 Aug; 24(24):3997-4002. PubMed ID: 16921053
[TBL] [Abstract][Full Text] [Related]
8. High-dose melphalan with autologous hematopoietic stem cell transplantation for acute myeloid leukemia: results of a retrospective analysis of the Italian Pediatric Group for Bone Marrow Transplantation.
Cesaro S; Meloni G; Messina C; Pillon M; Proglia A; Lanino E; Caniggia M; Bagnulo S; Pession A; Locatelli F;
Bone Marrow Transplant; 2001 Jul; 28(2):131-6. PubMed ID: 11509930
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of high-dose busulfan, melphalan and thiotepa with autologous stem cell support in patients with refractory malignancies.
Weaver CH; Bensinger WI; Appelbaum FR; Lilleby K; Sandmaier B; Brunvand M; Rowley S; Petersdorf S; Rivkin S; Gooley T
Bone Marrow Transplant; 1994 Nov; 14(5):813-9. PubMed ID: 7889015
[TBL] [Abstract][Full Text] [Related]
10. Myeloablative chemotherapy with autologous peripheral blood stem cell transplantation in patients with poor-prognosis solid tumors - Bulgarian experience.
Avramova B; Jordanova M; Michailov G; Konstantinov D; Christosova I; Bobev D
J BUON; 2006; 11(4):433-8. PubMed ID: 17309174
[TBL] [Abstract][Full Text] [Related]
11. [High-dose chemotherapy with autologous peripheral blood stem cell transplantation (PBSCT) for refractory bone and soft tissue sarcomas].
Yonemoto T; Tatezaki S; Ishii T; Satoh T
Gan To Kagaku Ryoho; 1999 Sep; 26(10):1431-5. PubMed ID: 10500530
[TBL] [Abstract][Full Text] [Related]
12. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
[TBL] [Abstract][Full Text] [Related]
13. Double-conditioning regimens consisting of thiotepa, melphalan and busulfan with stem cell rescue for the treatment of pediatric solid tumors.
Hara J; Osugi Y; Ohta H; Matsuda Y; Nakanishi K; Takai K; Fujisaki H; Tokimasa S; Fukuzawa M; Okada A; Okada S
Bone Marrow Transplant; 1998 Jul; 22(1):7-12. PubMed ID: 9678789
[TBL] [Abstract][Full Text] [Related]
14. Autologous stem cell transplantation for high-risk pediatric solid tumors.
Perentesis J; Katsanis E; DeFor T; Neglia J; Ramsay N
Bone Marrow Transplant; 1999 Sep; 24(6):609-15. PubMed ID: 10490725
[TBL] [Abstract][Full Text] [Related]
15. High-dose melphalan +/- total body irradiation and autologous hematopoietic stem cell rescue for adult patients with Ewing's sarcoma or peripheral neuroectodermal tumor.
Stewart DA; Gyonyor E; Paterson AH; Arthur K; Temple W; Schachar NS; Klassen J; Brown C; Russell JA
Bone Marrow Transplant; 1996 Aug; 18(2):315-8. PubMed ID: 8864440
[TBL] [Abstract][Full Text] [Related]
16. Absence of veno-occlussive disease in a cohort of multiple myeloma patients undergoing autologous stem cell transplantation with targeted busulfan dosage.
Clopés A; Sureda A; Sierra J; Queraltó JM; Broto A; Farré R; Moreno E; Brunet S; Martino R; Mangues MA
Eur J Haematol; 2006 Jul; 77(1):1-6. PubMed ID: 16573745
[TBL] [Abstract][Full Text] [Related]
17. Haploidentical stem cell transplantation in patients with pediatric solid tumors: preliminary results of a pilot study and analysis of graft versus tumor effects.
Lang P; Pfeiffer M; Müller I; Schumm M; Ebinger M; Koscielniak E; Feuchtinger T; Föll J; Martin D; Handgretinger R
Klin Padiatr; 2006; 218(6):321-6. PubMed ID: 17080334
[TBL] [Abstract][Full Text] [Related]
18. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.
Carreras E; Rosiñol L; Terol MJ; Alegre A; de Arriba F; García-Laraña J; Bello JL; García R; León A; Martínez R; Peñarrubia MJ; Poderós C; Ribas P; Ribera JM; San Miguel J; Bladé J; Lahuerta JJ;
Biol Blood Marrow Transplant; 2007 Dec; 13(12):1448-54. PubMed ID: 18022574
[TBL] [Abstract][Full Text] [Related]
19. Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin.
Bornhäuser M; Thiede C; Schuler U; Platzbecker U; Freiberg-Richter J; Helwig A; Plettig R; Röllig C; Naumann R; Kroschinsky F; Neubauer A; Ehninger G
Bone Marrow Transplant; 2000 Jul; 26(2):119-25. PubMed ID: 10918420
[TBL] [Abstract][Full Text] [Related]
20. Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies.
Small TN; Young JW; Castro-Malaspina H; Prockop S; Wilton A; Heller G; Boulad F; Chiu M; Hsu K; Jakubowski A; Kernan NA; Perales MA; O'Reilly RJ; Papadopoulos EB
Biol Blood Marrow Transplant; 2007 Feb; 13(2):235-44. PubMed ID: 17241929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]